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Resumo 
Introdução: O cancro da próstata representa uma das doenças oncológicas mais 
comuns em todo o Mundo, sendo o segundo cancro mais incidente nos homens a 
nível mundial e o quinto em termos de mortalidade. 80% dos tumores diagnosticados 
encontram-se ainda confinados ao órgão, pelo que a sua remoção cirúrgica por 
prostatectomia radical é possível, sendo um tratamento amplamente utilizado. No 
entanto, em mais de um terço dos pacientes sujeitos a esta terapia surge uma 
recorrência tumoral que se deverá a pequenas populações de células cancerígenas 
disseminadas, mas não detectadas, sendo necessários tratamentos adicionais, mais 
agressivos e que perturbam a qualidade de vida do doente. Na busca por marcadores 
não-invasivos que possam prever com maior certeza a probabilidade de uma 
recorrência surgir, os microRNAs surgem como candidatos devido à regulação 
epigenética que exercem na expressão de genes relacionados com o cancro, 
estando já descrito o seu papel crítico em doenças do foro oncológico tal como o 
cancro da próstata. 
Objetivos: Assim, o principal objectivo desta Dissertação foi estudar a expressão, no 
plasma, de dois microRNAs previamente descritos como potenciais oncogenes 
(miR-375 e miR-182) numa cohort de pacientes submetidos a prostatectomia radical, 
em dois momentos distintos: antes da cirurgia e durante o tempo de follow-up do 
doente. Posteriormente, procurou-se relacionar a expressão de microRNAs com a 
expressão dos mesmos microRNAs em tecido tumoral de um sub-grupo de pacientes 
e também com as variáveis clinicopatológicas de maior relevância. 
Material e Métodos: Após a extração de RNA de plasma e de tecido tumoral dos 
pacientes envolvidos e subsequente quantificação, procedeu-se à síntese de cDNA 
seguida da medição da expressão relativa do miR-375, do miR-182 e do gene de 
referência U6 snRNA por qRT-PCR. 
Resultados: Confirmou-se que o miR-375 e o miR-182 se encontram sobrexpressos 
em tecido tumoral comparando com tecido prostático normal. Ambos os microRNAs 
apresentam também uma maior expressão pré-operatória no plasma em pacientes 
com tumores em estadios mais elevados. Observou-se ainda que o rácio 
plasma:tecido da expressão do miR-375 é um preditor independente do tempo de 
sobrevivência livre de doença. Relativamente aos valores pós-operatórios de 
microRNAs, verificou-se que a expressão do miR-375 é mais elevada nos pacientes 
que desenvolveram recorrência bioquímica ou metastização comparando com os que 
não desenvolveram.  
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Discussão e Conclusões: O miR-375 desempenha um papel oncogénico em cancro 
da próstata, encontrando-se sobreexpresso no tecido tumoral comparativamente a 
tecido normal e também no plasma de doentes com progressão pós-operatória da 
doença, pelo que a sua expressão na circulação sanguínea pode ser um reflexo da 
progressão tumoral. Como tal, o miR-375 constitui um possível biomarcador para 
follow-up do paciente após cirurgia. Contrariamente, o papel oncogénico do miR-182 
deverá estar limitado aos estágios iniciais da carcinogénese prostática, uma vez que 
as diferenças de expressão encontradas (tecido e plasma) apenas se manifestam 
antes da realização da cirurgia e não durante o tempo de follow-up.  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Summary 
Introduction: Prostate cancer is one of the most common malignant diseases in the 
world, being the second most common cancer in men worldwide and fifth in terms of 
mortality. 80% of tumors are diagnosed in an organ-confined state, which permits its 
surgical removal by radical prostatectomy, a widely used treatment. However, a 
cancer recurrence arises in more than one third of the patients undergoing this 
therapy, perhaps due to small populations of disseminated cancer cells that remained 
undetected, therefore requiring additional and more aggressive treatments that disturb 
patient’s quality of life. microRNAs arise as candidates for noninvasive markers that 
can more accurately predict the likelihood of a recurrence due to their epigenetic 
regulation they exert in the expression of cancer-related genes as well as their critical 
role in malignant diseases such as prostate cancer. 
Aims: The main goal of this thesis was to study expression of two plasma-circulating 
microRNAs previously described as potential oncogenes (miR-375 and miR-182) in a 
cohort of patients undergoing radical prostatectomy at two different moments: at time 
of surgery and during patient's follow-up time. Subsequently, we investigated for 
associations between plasma expression of microRNAs and expression of the same 
microRNAs in tumorous tissue of a subgroup of patients as well as clinicopathological 
variables of major relevance. 
Material and Methods: After RNA extraction from plasma and tumor tissue of 
patients involved and subsequent RNA quantification, cDNA synthesis was performed 
followed by measurement of the relative expression of miR-375, miR-182 and the 
reference U6 snRNA gene by qRT-PCR. 
Results: We confirmed that miR-375 and miR-182 are overexpressed in tumor tissue 
compared to normal prostatic tissue. Both microRNAs also present a higher 
preoperative plasma expression in patients with higher-grade tumors. It was further 
observed that the plasma:tissue expression ratio of miR-375 is an independent 
predictor of disease-free survival time. Regarding the postoperative values of 
microRNAs, the expression of miR-375 was found to be higher in patients who 
developed biochemical recurrence or metastasis compared to those who did not. 
Discussion and Conclusions: miR-375 plays an oncogenic role in prostate cancer, 
being overexpressed in the tumor tissue compared to normal tissue and also in 
plasma of patients with disease progression after therapy, suggesting that its 
expression in patient bloodstream may be a reflex of tumor progression. As such, 
miR-375 is a possible biomarker for patient follow-up after surgery. Contrarily, the 
oncogenic role of miR-182 should be limited to the early stages of prostatic 
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carcinogenesis, since the expression differences in both tissue and plasma were 
limited to patients before radical prostatectomy and not during follow-up time.  
!viii
Table of Contents 
INTRODUCTION 1
1. The Prostate 1
1.1. Describing the Prostate Gland 1
1.2. From Benign Disorders to Prostate Cancer 2
1.3. Screening, Diagnosis and Prognosis of Prostate Cancer 5
1.4. Therapeutic Options for Prostate Cancer 9
1.5. The Arising of a Biochemical Recurrence 11
2. MicroRNAs 13
2.1. The World of Non-Coding RNA 13
2.2. MicroRNAs: Biogenesis and Functionality 13
2.3. MicroRNAs as Cancer Biomarkers 16
2.4. Prostate Cancer: Which Role for microRNAs? 17
2.4.1. miR-182 17
2.4.2. miR-375 18
AIM OF THIS STUDY 21
MATERIAL AND METHODS 22
1. The Cancer Genome Atlas dataset 22
2. Patients and sample collection 22
3. RNA extraction from Tissue 22
4. RNA extraction from Plasma 23
5. cDNA synthesis 23
6. miRNA expression analysis 24
7. Statistical analysis 25
RESULTS 26
1. MicroRNA Expression from TCGA dataset 26
2. MicroRNA Expression from PCa Tissue Validation Cohort 27
2.1. Tumor and MNPT: Expression Differences 27
2.2. Correlation with Clinicopathological Variables 28
2.3. Survival Analysis 29
!ix
3. Preoperative microRNA Expression in Plasma 30
3.1. Correlation with Clinicopathological Variables 30
4. microRNA Plasma:Tissue Ratio 32
4.1. Correlation with Clinicopathological Variables 32
4.2. Survival Analysis 33
5. Postoperative microRNA Expression in Plasma 34
DISCUSSION 36
CONCLUSION AND FUTURE PERSPECTIVES 39
ANNEXES 40
REFERENCES 45
!x
Figures Index 
Figure 1: Anatomy of human prostate gland and classification in zones. 2
Figure 2: Cancer incidence in males worldwide. 4
Figure 3: Cancer mortality in males worldwide. 5
Figure 4: H&E-stained sections illustrating the different Gleason patterns 
and corresponding Grade Groups.
7
Figure 5: The process of miRNA biogenesis. 15
Figure 6: Illustration of cDNA synthesis reaction. 24
Figure 7: Illustration of qPCR reaction. 25
Figure 8: Expression of miR-375 in malignant and normal tissue from TCGA 
dataset.
26
Figure 9: Expression of miR-182 in malignant and normal tissue from TCGA 
dataset.
26
Figure 10: miR-375 and miR-182 expression levels in tumor and healthy 
tissue.
28
Figure 11: Linear regression of miR-375 (A) and miR-182 (B) levels and 
preoperative PSA value of each patient.
29
Figure 12: miR-375 expression levels stratified by Grade Groups and 
dichotomized into low and high grade.
30
Figure 13: miR-182 expression levels stratified by Grade Groups and 
dichotomized into low and high grade.
31
Figure 14: miR-375 and miR-182 expression levels stratified by pathological 
stage. 
31
Figure 15: miR-375 and miR-182 plasma:tissue ratio levels stratified by 
pathological stage.
33
Figure 16: Kaplan-Meier BCR-free survival time of patients with high and 
low preoperative miR-375 and miR-182 plasma-tissue ratio.
33
Figure 17: Levels of postoperative plasma-circulating miR-375 and miR-182 
according to the developed outcome after surgery. 
35
Figure 18: Linear regression of miR-375 and miR-182 levels and 
postoperative PSA value of each patient.
35
!xi
Tables Index 
Table 1: TNM classification for PCa by the UICC/AJCC. 8
Table 2: Target sequence of TaqMan microRNA expression assays. 24
Table 3: Description of clinicopathological variables of patients included in 
this study.
27
!xii
List of Abbreviations 
AA African american
ADT Androgen-deprivation therapy
AFS Anterior fibromuscular stroma
AJCC American Joint Committee on Cancer
ANOVA Analysis of variance 
ARRDC3 Arrestin domain containing 3
AS Active surveillance
AUC Area under the curve
BCL2 B-cell lymphoma 2
BCR Biochemical recurrence
BPH Benign prostatic hyperplasia
BRCA2 Breast cancer 2
CBX7 Chromobox 7
CRPC Castration-resistant prostate cancer
CYP17 Cytochrome P450 17A1
CYP19 Aromatase cytochrome P450
CZ Central zone
DNA Deoxyribonucleic acid
DGCR8 DiGeorge syndrome critical region 8 
DRE Digital rectal examination
EBRT External-beam radiotherapy
ERG Erythroblast transformation-specific related gene
FIH1 Factor inhibiting hypoxia-inducible factor 1α
FOXF2 Forkhead box F2
FOXO1 Forkhead box protein O1
GEO Gene Expression Omnibus
GNA13 G-protein subunit α-13
GG Grade group
GS Gleason score
!xiii
HGPIN High-grade prostate intraepithelial neoplasia
HIF-1α Hypoxia-inducible factor 1α
LUTS Lower urinary tract symptoms
MET Mesenchymal-epithelial transition
miR MicroRNA
miRNA MicroRNA
MNPT Matched normal prostatic tissue
mRNA Messenger ribonucleic acid
MRI Magnetic resonance imaging
MTSS1 Metastasis suppressor protein 1
NDRG1 N-myc downstream regulated gene 1
PBMC Peripheral blood mononuclear cells
PCa Prostate cancer
PDH2 Prolyl hydroxylase domain-containing protein-2
PHLPP1 PH domain and leucine-rich repeat protein phosphatase 1
PIN Prostate intraepithelial neoplasia
pre-miRNA Precursor microRNA
pri-miRNA Primary microRNA
PSA Prostate-specific antigen
PZ Peripheral zone
qPCR Quantitative polymerase chain reaction
qRT-PCR Quantitative reverse transcription polymerase chain reaction
RECK Reversion-inducing cysteine-rich protein with kazal motifs
RISC RNA-induced silencing complex
RNA Ribonucleic acid
RP Radical prostatectomy
Sec23A Sec23 homolog A (Saccharomyces cerevisiae)
SNAI2 Snail Family Transcriptional Repressor 2
SRD5A2 Steroid α-reductase type 2 gene
snRNA Small nuclear ribonucleic acid
snoRNA Small nucleolar ribonucleic acid  
!xiv
suPAR Soluble urokinase plasminogen activator receptor 
TCGA The Cancer Genome Atlas
TMPRSS2 Transmembrane protease, serine 2
TRBP1 Transactivating response RNA binding protein
TRUS Transrectal ultrasound
TZ Transitional zone
UICC Union for Cancer Control
UTR Untranslated region
WW Watchful waiting
XPO5 Exportin 5
YAP-1 Yes associated protein 1
ZEB-1 Zinc finger E-box binding homeobox 1
!xv
Introduction 
1. The Prostate 
1.1. Describing the Prostate Gland 
  
 Being an integral part of male reproductive system, the prostate gland is a 
small exocrine organ located underneath the bladder and in front of the rectum. It is 
traversed by the urethra and the ejaculatory ducts and plays a crucial role on the 
nourishment and protection of sperm. During an ejaculation, sperm is released by the 
testicles and travels through the vas deferens until the seminal vesicles, which secrete 
a significant proportion of the liquid that becomes the semen. Then the resulting fluid 
enters the ejaculatory ducts and crosses the prostate gland, which is responsible for 
the secretion of proteins and hormones which are added to the semen and 
concomitantly released into the urethra [1].  
 In an adult male, a healthy prostate gland has an approximate volume of 20 to 
25 cm3 [2] and an estimated weight of 20 grams [3], resembling the size and shape of 
a walnut. The prostate gland encompasses (1) a stromal component comprised of 
connective tissue which essentially provides functional support and (2) a glandular 
component mainly composed of ducts, which allow draining of the prostatic fluid into 
the urethra, and acini, which are microscopic glands located at the end of the smaller 
ducts and rounded by secretory epithelial cells responsible for the production of the 
prostatic contribution to ejaculatory fluid [4]. Both stromal and glandular components 
are numerously found throughout the prostate gland.  
 Although a segmentation in lobes was previously thought for human prostate, 
the homogeneous appearance of prostate surfaces led John E. McNeal to suggest in 
1969 a division in four different zones [5], a classification that is widely used 
nowadays (Figure 1). The peripheral zone (PZ) is comprised of glandular tissue and 
located at the back of the prostate closest to the rectum. It surrounds the distal 
urethra, constituting about 70% of the gland and being the origin place of about 75% 
of carcinomas as well as other prostatic pathologies [6, 7]. The central zone (CZ) is a 
cone-shaped portion that encircles the ejaculatory ducts and accounts for 25% of the 
organ. Only about 15% of prostatic cancers arise in CZ, however they tend to be more 
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aggressive due to their proximity to the seminal vesicles, which increases the 
likelihood of invasion [8]. Together PZ and CZ represent 95% of the prostatic gland. 
The transition zone (TZ) is the innermost component of the gland and surrounds the 
urethra representing only 5% of the organ at puberty. However, TZ tends to 
continuously enlarge throughout life and thus the development of age-related benign 
pathologies as well as 10-15% of cancers is frequent in this region. The anterior 
fibromuscular stroma (AFS) makes up less than 5% of the gland and it is located at 
the front of the prostate gland closest to the abdomen. It covers the anterior external 
surface and it is enriched in striated muscle tissue, therefore lacking glandular 
components [3].  
1.2. From Benign Disorders to Prostate Cancer 
 The normal development and growth of the prostate gland is promoted by the 
androgen-signaling pathway in which androgens induce gene transcription and 
subsequent cell proliferation by binding to the androgen receptor (AR) located in cell 
membrane. Testosterone, mainly produced by testicular Leydig cells is the primary 
androgen of the human body, however its metabolite dihydrotestosterone (DHT) 
arises as a more potent androgen with three times higher affinity to the AR and a 5-
fold increase in binding time [9]. Testosterone synthesis, conversion to DHT, transport 
of DHT to target cells and binding to the AR are therefore the main steps of androgen-
signaling axis [10]. DHT is thought to maintain the balance between cell proliferation 
and cell death and gradual disruption of this equilibrium may account for the 
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Figure 1: Anatomy of human prostate gland and classification in zones (adapted from [7]). ED = 
ejaculatory ducts; SV = seminal vesicles; AFS = anterior fibromuscular stroma.
progressive enlargement of prostate gland throughout life even during adulthood, 
thereby explaining the high incidence of prostate growth-related disorders among 
elderly individuals [10]. 
 One of the most common benign diseases worldwide is benign prostatic 
hyperplasia (BPH), affecting approximately 50% of men between 51 and 60 years old 
and 90% of men with more than 80 years old [11, 12]. BPH is characterized by a 
uncontrolled increase in the number of prostatic cells leading to an overgrowth of 
nonmalignant tissue and usually arises within the TZ of the prostate gland surrounding 
urethra thus potentially interfering with the normal flow of urine. In fact, BPH-related 
lower urinary tract symptoms (LUTS) arise in 25% of men between 50 and 59 years 
old and 50% of men with more than 80 years old [12] and frequently involve urinating 
difficulties. As previously reviewed [13], BPH and prostate cancer (PCa) share several 
traits namely (1) the androgen-dependent growth; (2) the rise with increasing age, 
with an estimated 15-year lag between both pathologies [12, 14]; (3) common clinical 
events such as prostatic inflammation (prostatitis), which prompts both BPH [15] and 
PCa [16] development; and (4) shared genetic alterations that increase the risk of 
both BPH and PCa such as variants of androgen-related CYP17, CYP19 and 
SRD5AR genes [17-19]. However, a causal link between BPH and PCa is not clearly 
characterized. Histologic differences between both pathologies as well as differences 
in anatomic localization within the prostate gland and the lack of evidence of BPH as 
an initial disorder in the pathway to PCa suggest that aforementioned associations 
between BPH and PCa may be due to a coexistence of both pathologies rather than a 
causal relationship [20]. For these reasons, BPH is not currently considered a 
precursor of PCa or a premalignant lesion. 
 Prostatic intraepithelial neoplasia (PIN) is defined by a “neoplastic growth of 
epithelial cells within preexisting benign prostatic acini or ducts” [21]. When PIN 
develops, epithelial cells from acini or ducts of the prostate become abnormal, yet 
without functional disruption. According to the histological grading of malignant cells, 
PIN may be subdivided in low- and high-grade (HGPIN) categories, being the latter 
considered a percursor of PCa with an estimated 10-year lag [22]. HGPIN and PCa 
share a variety of features, mainly concerning (1) statistical data, with 73% of prostate 
glands that harbor cancer having HGPIN lesions, compared to 32% of healthy glands 
[23]; (2) molecular alterations such as loss of chromosome 8p, gain of 8q or harboring 
of TMPRSS2-ERG fusion gene [22]; and (3) the partial lack of a basal cell layer in 
HGPIN, which further validates HGPIN as a precursor lesion due to the absence of 
basal cells in PCa, suggesting a progressive loss of this feature [22]. Although not all 
prostate tumors necessarily result from the development of a HGPIN lesion, the 
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degree of similarities between HGPIN and PCa suggests a causal relationship. 
Therefore, HGPIN currently remains the most well-established and likely percursor of 
PCa. 
 Prostate adenocarcinoma arises as the most common malignant disorder in 
the prostate, being an extensively heterogeneous pathology which can lead to very 
different outcomes, from clinically indolent to extremely aggressive ones. Prostate 
adenocarcinoma accounts for about 95% of prostate cancers, hence being usually 
designated by ‘prostate cancer’ or PCa as a matter of simplification. The majority of 
prostate cancers are acinar adenocarcinomas, while other tumor categories such as 
ductal or mucinous adenocarcinoma are extremely rare [24]. Considering worldwide 
cancer statistics in males, PCa is currently the second most incident cancer in males 
(Figure 2) but only the fifth leading cause of death from cancer (Figure 3), with an 
estimated 1.1 million new cases and 307,000 deaths in 2012 [25]. In Portugal 6,622 
new cases of PCa were diagnosed in 2012, being the most incident cancer in males 
and the third most lethal cancer with 1,582 registered deaths [25]. These numbers 
clearly demonstrate that PCa is a relevant health concern nowadays.  
 
  
 In spite of being a very common and widespread disease, there are only three 
well-characterized risk factors for PCa: age, ethnicity and family history [26]. All of 
them are inevitable and do not directly depend on any human behavior, which restricts 
the possibility of a widespread action on disease prevention. Age is the most relevant 
risk factor: the risk of having PCa is negligible until age 50 but rises after age 55 and 
reaches a peak at 70-74 years [27]. Ethnicity also plays an important role, with African 
American (AA) patients having higher risk than their counterparts, with more than 
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Figure 2: Cancer incidence in males worldwide [25].
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twice of the mortality rate compared to Caucasian Americans [28]. Reasons for this 
phenomena are still widely unknown, although chromosome 8q24, which is one of the 
most commonly amplified chromosomal regions may, at least partially, explain the 
higher incidence in AA men [29]. Family history also increases the risk of developing 
the disease: a brother or father with PCa at least doubles the risk of a man having 
PCa [27] and it may increase until 17 times depending on the number of affected first-
line relatives [30]. About 9% of diagnosed men have hereditary PCa, which anticipates 
the onset for 6-7 years [26], but only the presence of a germline BRCA2 mutation has 
shown an increased risk of early and aggressive disease [31, 32]. Additional risk 
factors such as diet [33] or metabolic syndrome [34] have been proposed, however 
without sufficiently clear evidence.  
1.3. Screening, Diagnosis and Prognosis of Prostate Cancer 
  
 The goal of PCa screening is to detect cancer before symptoms arise. The two 
most widely screening tools are prostate-specific antigen (PSA) level in serum and 
digital rectal examination (DRE), an examination in which a physician directly 
assesses prostatic abnormalities by finger examination of the prostate gland through 
the rectum.  
 PSA is a serine protease produced by prostatic epithelial cells whose function 
is to cleave semenogelins from the gel matrix of the seminal coagulum, allowing 
sperm to move freely [35]. PSA test was approved in 1986 for monitoring disease 
progression and in 1994 (together with DRE) for screening asymptomatic man. Two 
large randomized studies have shown that PSA screening increased the diagnosis 
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Figure 3: Cancer mortality in males worldwide [25].
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rate particularly at early stages of cancer development, but the existence of a benefit 
in overall survival or cancer-specific survival is unclear [36, 37]. These observations 
have generated controversy regarding the use of PSA test because it could be 
responsible for the detection of non life-threatening tumors (overdiagnosis) and 
subsequent unnecessary treatment (overtreatment) [38]. Furthermore, PSA is 
prostate-specific but not cancer-specific and other prostatic pathologies such as 
prostatitis or BPH may increase PSA levels leading to false-positive results. In fact, 
PSA-based screening represents a high economic burden for PCa: 1410 men are 
needed to be screening and 48 PCa cases to be treated in order to prevent one 
disease-related death [37]. Therefore, PSA test remains a useful screening tool but 
widespread screening is not recommended and its use should be limited to men 
expressing preference for screening [26, 39]. 
 According to present guidelines, men with serum PSA higher than 4 ng/mL 
and/or abnormal result from DRE must perform a prostate biopsy. The transrectal 
ultrasound (TRUS)-guided biopsy is the gold-standard method for the obtainment of 
prostate tissue samples for histological studies. 10 to 12 cores should be obtained 
from different parts of the prostate gland and additional cores may be obtained from 
suspicious areas [26]. Definite diagnosis is not limited to PSA level or DRE result and 
always depends on the histological confirmation of a cancerous lesion by prostate 
biopsy.  
 In order to determine the prognosis of PCa and the most appropriate 
therapeutic option for each patient, tumor staging and grading emerge as the two 
most valuable parameters regarding PCa characterization. 
   
 PCa staging is an indicator of how far the cancer has spread. Given the 
importance of knowing cancer extension to successfully evaluate prognosis and plan 
the treatment, efforts have been made in order to find a standardized staging system 
for clinical application [40]. The TNM system is currently the most broadly used 
staging tool and it evaluates three different components: the local staging, which is the 
extension of primary tumor (T); the involvement of lymphatic nodes (N); and the 
presence of metastases (M). According to the timing and source of data collection, 
PCa staging may be subdivided in (1) clinical stage (cT), which is the information on 
cancer extension that is collected prior to treatment onset; and (2) pathological stage 
(pT), which is determined after direct macroscopic and microscopic examination of the 
surgical specimen and thus only obtained after radical prostatectomy. Pre-treatment 
local staging (T) is based on DRE findings and possibly MRI and it is obtained for all 
patients, while lymph-node staging (N), which is preferentially measured by nodal 
!6
evaluation, or metastatic staging (M), achieved by bone scan, are only performed in 
high-risk patients [41]. A summary of the used criteria for tumor staging according to 
TNM system can be seen below in Table 1.  
 PCa grading consists of the measurement of the microscopic features of 
cancer cells to estimate the aggressiveness of the tumor. Named after Donald F. 
Gleason’s proposal in 1966, the Gleason grading system is the most widely used tool 
for PCa grading. Cancer cells are classified according to their differentiation status 
from Grade 1 (most differentiated) to Grade 5 (least differentiated) and Gleason Score 
(GS) is calculated by the sum of the grade of the most extensive component with the 
sum of the highest grade regardless of its extent. Consequently, GS may vary 
between 2 (1+1) and 10 (5+5) [41]. The concept of Grade Group (GG) was recently 
proposed in an attempt to more accurately simplify the high GS number for clinically 
irrelevant tumors and to distinguish important differences between GS 7 (3+4) and GS 
7 (4+3) tumors [42]. Therefore GG 1 to 5 account for GS ≤ 6, GS = 7 (3+4), GS = 7 
(4+3), GS = 8 and GS = 9, respectively and these prognostically distinct groups must 
be clinically used in conjunction with the previous Gleason Score concept [26, 43], as 
illustrated in Figure 4.  
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Figure 4: H&E-stained sections illustrating the different Gleason patterns and corresponding Grade 
Groups (adapted from [43]).
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Clinical Stage
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Clinically inapparent tumor that is not palpable
T1a Tumor incidental histologic finding in 5% or less of tissue resected
T1b Tumor incidental histologic finding in more than 5% of tissue resected
T1c Tumor identified by needle biopsy found in one or both sides, but not palpable
T2 Tumor is palpable and confined within prostate
T2a Tumor involves one-half of one side or less
T2b Tumor involves more than one-half of one side but not both sides
T2c Tumor involves both sides
T3 Extraprostatic tumor that is not fixed or does not invade adjacent structures
T3a Extraprostatic extension (unilateral or bilateral)
T3b Tumor invades seminal vesicle(s)
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles, such as 
external sphincter, rectum, bladder, levator muscles, and/or pelvic wall
Pathological Stage
T2 Organ confined
T3 Extraprostatic extension
T3a Extraprostatic extension (unilateral or bilateral) or microscopic invasion of 
bladder neck
T3b Tumor invades seminal vesicle(s)
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles, such as 
external sphincter, rectum, bladder, levator muscles, and/or pelvic wall
Nx Regional lymph nodes were not assessed
N0 No positive regional lymph nodes
N1 Metastases in regional lymph node(s)
M0 No distant metastasis
M1 Distant metastasis
M1a Nonregional lymph node(s)
M1b Bone(s)
M1c Other site(s) with or without bone disease
Table 1: TNM classification for PCa by the UICC/AJCC (adapted from [40]).
 Considering the referred classification systems for tumor staging, three risk 
groups with different expected outcomes have been defined for patients diagnosed 
with PCa [26]. Low-risk PCa harbors organ-confined tumors with PSA < 10 ng/mL, GS 
< 7 and cT 1-2a. Intermediate-risk PCa accounts for localized tumors with at least one 
of the following conditions: PSA 10-20 ng/mL, GS 7 or cT 2b. High-risk PCa englobes 
locally advanced tumors with any PSA level or GS and with cT 3-4 or cN+ as well as 
organ-confined tumors with at least one of the following conditions: PSA > 20 ng/mL, 
GS > 7 or cT 2c [26]. The risk group constitutes an extra tool for the physician to 
choose one of the available therapeutic options, however other important aspects 
such as life expectancy, comorbidities or therapeutic side effects must be taken into 
account in order to further perform a personalized therapeutic approach.  
1.4. Therapeutic Options for Prostate Cancer 
  
 Considering that (1) PCa frequently affects elderly man; (2) about 80% of 
prostate tumors are presumably detected in an early, organ-confined stage [44] and 
(3) patients with low-risk PCa present high 15- and 20-year survival rates [45, 46], one 
of the main challenges regarding PCa treatment nowadays is the prevention of 
overtreatment of clinically irrelevant tumors that are very unlikely to kill the patient. 
Active surveillance (AS) emerges a strategy where low-risk patients are not treated 
but instead kept under surveillance through systematic DRE and PSA tests and 
eventually rebiopsies. Patients under AS harbor tumors that are characterized by a 
very slow growth. This approach allows them to be spared from adverse effects of 
radical therapy and still benefit from therapy with curative intent in case of cancer 
progression [47]. This approach is currently limited to patients within tumor-confined 
stages (cT2 or less), GS equal or less than 6, serum PSA levels below 10 ng/mL and 
more than 10 years of life expectancy [26]. Some studies have shown a high 10-year 
disease-specific survival for AS patients with levels comparable to those who 
performed radical therapies [48, 49]. Watchful waiting (WW) is a similar procedure in 
which patients with a life expectancy inferior to 10 years who are not candidates for 
radical therapy are closely followed and noncurative treatment is applied only in case 
of development of symptoms. This approach is more frequent among very old patients 
(since it is very unlikely that the tumor kills the patient due to his advanced age) and 
its main goal is to minimize treatment-related toxicity and side effects. It has been 
reported that there was no difference in 10-year overall survival and cancer-specific 
survival for low-risk patients when comparing WW and radical surgery, which thereby 
supports this novel therapeutic approach [50]. 
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 Among non-conservative therapeutic possibilities, radical prostatectomy (RP) 
arises as one of the most common procedures and its purpose is the complete 
surgical removal of the prostate gland and seminal vesicles without compromising the 
normal functioning of urinary and, when possible, the reproductive system. RP is 
limited to patients with organ-confined disease, PSA values below 20 ng/mL and life 
expectancy of more than 10 years [26]. RP may be performed in low-, intermediate- 
and high-risk patients, however extraprostatic extension and GS > 7 are common 
contraindications for the latter group. Complementary therapies such as extended 
nodal dissection are frequently performed particularly in high-risk patients. RP has 
shown a benefit in overall and disease-specific survival for intermediate-risk patients 
compared with WW [51], although side effects such as postoperative incontinence or 
erectile dysfunction may arise. External-beam radiotherapy (EBRT), a therapeutic 
option in which tumor is eradicated through external emission of ionizing radiation, 
and brachytherapy, where small radiation-emitting beads are implanted nearby the 
tumor leading to an internal emission of radiation are also curative treatment choices 
with benefits similar to RP [52]. 
 Despite the high proportion of PCa cases within a localized tumor stage at 
time of diagnosis, about 20% of patients are diagnosed within an advanced stage. 
Due to the almost ubiquitous expression of AR in PCa cells and their dependence on 
androgens for growth and proliferation, virtually all prostate tumors are androgen-
responsive at least on their early stages [53]. Based on this principle, androgen 
deprivation therapy (ADT) accounts for the suppression of androgen production and 
remains the standard procedure for non-localized PCa, being also frequently used as 
an adjuvant therapy after curative treatment and also as a neo-adjuvant option before 
primary treatment (particularly among patients with higher GS at time of biopsy) as 
well as a second-line therapy in patients who developed a cancer relapse after initial 
treatment. The two main methods for androgen deprivation are (1) surgical castration, 
involving a bilateral orchidectomy (surgical excision of the testicles), which quickly and 
effectively reduces testosterone levels in circulation [54] but leads to a strong 
decrease in quality of life and patient regretfulness due to its irreversible nature [55, 
56]; and (2) medical castration, where decreased androgen levels are caused by the 
administration of drugs that manipulate the hypothalamic–pituitary–gonadal axis, 
which is responsible for hormone production [56]. Although strong improvements on 
ADT have been achieved in the last years, eventually all tumors evolve into a 
castration-resistant prostate cancer (CRPC) stage, in which cancer is able to 
overcome the androgen-dependence and maintain its growth by activating alternative 
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proliferation pathways. CRPC is the final and incurable stage of PCa and inevitably 
leads to patient death. On average, it arises only 18 months after hormone treatment 
[57]. At this point, docetaxel-based chemotherapy is a common therapeutic option but 
with an estimated survival benefit of merely 2 months [58]. Most of CRPC patients 
present painful metastases and their treatment is restricted to palliative options. 
1.5. The Arising of a Biochemical Recurrence 
 When a patient is submitted to a radical therapeutic option such as RP or 
EBRT, cancer cells are thought to have been surgically removed or effectively killed 
through irradiation, respectively. However, it is estimated that 35% of patients that 
underwent RP and 30% of patients who performed EBRT will develop a biochemical 
recurrence (BCR) within 10 years [59, 60]. Since both therapeutic options are limited 
to patients with presumably organ-confined disease, it is reasonable to assume that 
BCR happens because undetectable subpopulations of cancer cells have spread 
beyond the prostatic gland and managed to escape primary treatment and survive.  
 After performance of RP, PSA value is expected to fall to undetected levels, 
since the prostate has been removed, whereas EBRT-treated patients may have a low 
but detectable postoperative PSA, which is called PSA nadir. It is currently accepted 
that a PSA level > 0.2 ng/mL upon two consecutive increases after RP represents a 
BCR [61], while BCR after EBRT is represented by a PSA value of 2 ng/mL above 
PSA nadir [62]. Postoperative PSA test is considered an appropriate tool to monitor 
the occurrence of BCR after treatment. In fact, similarly to all prostatic cells, cancer 
cell populations which survived curative therapy produce PSA and may, at some point, 
proliferate and generate detectable levels of PSA in serum. Nevertheless we should 
have in mind that PSA is prostate-specific but not cancer-specific and thus a 
detectable PSA level should not be seen as a certainty of the presence of cancer cell 
populations, since it may reflect, for instance, the presence of residual benign tissue 
[63].  
 In patients with BCR, less therapeutic options are available. Salvage 
radiotherapy is a common and effective therapeutic choice with post-therapy PSA 
values falling to undetectable levels in about 60% of patients [64]. ADT also emerges 
as a possible salvage treatment, however its use as a second-line therapy after RP 
must not be offered to asymptomatic patients with BCR or patients with high PSA 
doubling times and thus very low progression rates [26].  
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 Although PSA is a commonly used tool during patient follow-up after treatment, 
its ability to predict the occurrence of a BCR before therapy is very limited. In fact, 
clinicopathological features such as Gleason score, surgical margin status or 
pathological stage have only shown a limited association with BCR-free survival time 
[65]. Therefore, recalling that BCR may arise due to the existence of micrometastatic 
cancer cells spread beyond the prostatic gland, a biomarker that could detect the 
presence of those cancer cell subpopulations before the performance of RP is needed 
in order to determine if BCR is likely to happen and thus RP and/or adjuvant 
treatments are needed. Monitoring cancer cells detachment and invasion at a 
molecular level would certainly allow a more effective treatment choice and reduce 
patient anxiety, the number of postoperative relapses and consequently the need for 
further treatment with inevitably associated side effects.  
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2. MicroRNAs 
2.1. The World of non-coding RNA 
 Enunciated by Francis Crick in 1958, the “central dogma of molecular biology” 
firstly proposed that biological information is uniquely stored in the nucleotide 
sequence of DNA and flows unidirectionally from DNA to RNA and from RNA to 
protein [66]. Although some adjustments to this theory were posteriorly performed, 
highlighting that a backward flux of information from RNA to DNA was equally possible 
mainly due to published works reporting the use of viral RNA as a template for DNA 
synthesis in the context of infection and transformation by viruses [67], RNA was 
initially seen as a merely transient form of information between DNA and protein. 
However, protein-coding DNA is estimated to constitute less than 2% of the human 
genome [68] contrasting with the fact that almost all genome is transcribed at some 
level [69], which brought into question the role of RNA transcripts resulting from non-
protein-coding DNA (previously called junk DNA due to its apparent uselessness). 
 These different forms of RNA, generally referred to as “non-coding RNA”, 
include not only the well-characterized ribosomal RNA and transfer RNA but also new 
recently found classes of RNAs such as snRNAs, snoRNAs, circular RNAs and — of 
particular interest for this work — microRNAs. Despite their general low expression 
levels [70], the functionality of many of these forms of non-coding RNA has been 
progressively demonstrated, inevitably challenging the way non-coding RNAs are 
seen in context of gene expression within the cell [71]. 
2.2. MicroRNAs: Biogenesis and Functionality 
 MicroRNAs (miRNAs; miR) are very small non-coding RNA molecules with an 
average of only 22 nucleotides. They are able to suppress gene expression at the 
level of translation by directly interacting with (and thereby silencing) molecules of 
mRNA [72]. Firstly discovered in 1993 through developmental studies on nematode 
Caenorhabditis elegans, miRNAs have been shown to exert their action by directly 
matching the 3’-untranslated regions (UTRs) located at the end of their mRNA targets 
[73, 74]. In the last 20 years, knowledge on miRNA field has been exponentially 
expanding, particularly concerning miRNA biogenesis, their modus operandi and their 
role whether during normal homeostasis or the development of several pathologies.  
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 One of the most relevant aspects of miRNA biology is their promiscuous 
association with mRNA molecules: a single miRNA may regulate dozens of different 
transcripts whereas the same mRNA molecule may be targeted by several different 
miRNAs [75, 76]. Accordingly, miRNAs have been virtually linked to all normal and 
pathological processes, being estimated that up to 60% of protein-coding gene 
expression may be regulated by miRNA activity [72]. Moreover, miRNA expression 
has also been shown to be extensively tissue-specific allowing the identification of 
specific miRNA expression profiles for each cell type. Although putative functions of 
individual miRNAs have progressively been unveiled mainly through ectopic 
expression studies, loss-of-function studies carrying individual inactivation of miRNAs 
have rarely shown to dramatically change gene expression levels and to have strong 
phenotypic consequences. This suggests that miRNAs may act not as strong 
expression repressors but rather as gene expression fine-tuners that guarantee rapid 
and cell-dependent changes in protein synthesis without altering upstream 
transcription process [77].  
  
 There are currently 1,881 homo sapiens miRNA sequences that have been 
identified and published on miRBase, a widely used online miRNA repository [78]. 
However, due to the small size of miRNAs, it is quite difficult to assure that a certain 
sequence is indeed a miRNA and it has been proposed that many of these putative 
miRNAs are false positives considering only 523 sequences to be bona fide miRNA 
genes [79]. Between 50-80% of miRNA genes are thought to be localized at intronic 
regions (i.e., segments of DNA that do not code for protein) within host genes [80, 81] 
and their transcription results from further processing of the removed introns as part of 
the normal host gene transcription. Alternatively, miRNA genes can be found in 
intergenic regions and transcribed as individual units or gene-independent clusters 
containing several different miRNAs [82].  
 A summary of the most relevant steps of miRNA biogenesis can be seen in 
Figure 5 [83]. Transcription of miRNA genes is performed by RNA polymerase II, 
generating transcripts named pri-miRNAs with variable length (usually between 
1000-3000 nucleotides) that harbor a region of imperfect double-strand 
complementarity, called a stem-loop structure, where the future mature miRNA is 
contained [84]. This region is recognized by the ‘human microprocessor’, a protein 
complex formed by DGCR8 protein that binds to the pri-miRNA and ribonuclease 
Drosha which further processes pri-miRNAs by enzymatic cleavage, generating a 65-
nucleotide-long hairpin-shaped precursor-miRNA (pre-miRNA) with two arms attached 
by a loop [85]. An alternative mechanism to this canonical pathway has also been 
reported: due to their small size, miRNAs arising from very short introns — referred to 
!14
as mirtrons — are processed by the normal splicing machinery and at this point its 
structure already mimics the pre-miRNA structure, therefore being able to bypass 
Drosha-DGCR8 cleavage [86]. 
 All previously described steps take place within cell nucleus. Thereafter, pre-
miRNA is transported to the cytoplasm via Exportin 5 (XPO5) and further cleaved by 
ribonuclease Dicer, which together with transactivator-RNA binding protein (TRBP1) 
removes the loop portion, giving rise to a duplex formed by two short and partially 
complementary RNA strands [87]. This duplex is composed of a guide strand holding 
the mature miRNA and a passenger strand which contains the miRNA*, a species that 
is usually degraded and thus much less abundant than the correspondent miRNA — 
for instance, miR-182 and miR-182* share the same pre-miRNA but miR-182 is much 
more extensively expressed. However, it is noteworthy that both arms may have 
similar expression levels and therefore should be nominally distinguished with a -5p 
suffix and a -3p suffix for guide and passenger strands respectively — for instance, 
miR-28-5p and miR-28-3p share the same pre-miRNA and both are expressed [88].  
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Figure 5: The process of miRNA biogenesis (adapted from [83]). 
 The mature miRNA is then transferred to Argonaute proteins via TRBP1 
assembling the RNA-induced silencing complex (RISC), a protein complex that 
effectively regulates gene expression by enabling miRNA-mRNA matching and 
subsequent inhibition of mRNA translation [82]. Tridimensional structure of RISC 
complex allows the exposure of miRNA seed sequence, the portion of miRNA 
comprised between nucleotides 2-8 that effectively matches the 3’UTR of mRNA [89]. 
The degree of miRNA-mRNA complementary determines the outcome of miRNA 
regulation: a perfect or near-perfect match between miRNA and mRNA (above 95% of 
complementarity) target induces mRNA cleavage and subsequent destruction, 
although this is considered a very rare phenomenon in mammals; contrarily, an 
imperfect complementarity (below 95%) leads to a translation repression [90]. Notably, 
some miRNAs have been described as translation activators instead of repressors 
[76], although this surprising regulation phenomena remains an exception and not the 
rule. 
2.3. MicroRNAs as Cancer Biomarkers 
  
 Following the expectations of miRNAs to be linked to virtually all biochemical 
processes including disease development, researchers have focused on exploiting the 
association between miRNAs and different steps of carcinogenesis during the last 15 
years. In 2002 miRNAs were firstly described to be differentially expressed in cancer 
by Calin et al. who demonstrated that miR-15a & miR-16-1 cluster was downregulated 
in B cells of patients suffering from chronic lymphocytic leukemia [91]. Subsequent 
studies on different cancer types were published suggesting a global and consistent 
miRNA deregulation in cancer [92, 93]. Since miRNAs promote a repression on gene 
expression, miRNAs that target mRNAs encoding oncogenes (i.e., genes with 
potential of promoting cancer development) are classified as tumor suppressor 
miRNAs, while miRNAs inhibiting the expression of tumor suppressor genes are 
defined as oncogenic miRNAs or oncomiRs [94]. Therefore, a global deregulation of 
miRNA profile involving loss of tumor supressor miRNAs and gain of oncogenic 
miRNAs is thought to be closely related with cancer development.  
 Putative mechanisms of miRNA loss and gain are thought to be similar to the 
ones that drive repression of tumor suppressor genes and activation of oncogenes 
[94]. Loss and gain of miRNA expression has been associated not only with genetic 
alterations such as chromosomal deletions [91], amplifications or mutations [95] but 
also due to epigenetic mechanisms such as promoter hypermethylation [96] or histone 
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modifications [97]. This hypothesis is further sustained by studies reporting that 
miRNA genes are frequently located within fragile genomic regions that usually give 
rise to cancer-related aberrant genomic alterations [98]. 
 Since miRNA expression signatures differ between cancer and normal tissue 
and also between cancer subtypes in a very consistent way, miRNAs have 
progressively emerged as stable cancer-specific biomarkers that can help to 
determine diagnosis, prognosis, treatment response and other clinical parameters of 
patients with cancer. Importantly, in 2008 miRNAs have been found to circulate in 
biological fluids, such as plasma or serum, with a remarkable stability [99], thereby 
broadening their potential both as tumor-confined and fluid-circulating biomarkers. 
However, it is fundamental to clarify the origin and putative biological role of a plasma-
circulating miRNA in a patient diagnosed with cancer. As recently reviewed, cancer 
cells or cells from tumor microenvironment may actively release tumor-promoting 
miRNAs into blood circulation, but healthy blood cells such as peripheral blood 
mononuclear cells (PBMC) might also secrete tumor-suppressive miRNAs with as part 
of host response against cancer [100], and thus a cautionary approach should be 
performed regarding the potential of miRNAs as circulating biomarkers in cancer. 
2.4. Prostate Cancer: Which Role for microRNAs? 
  
 Being one of the major concerns in the context of malignant diseases due to 
its very high incidence among male population, efforts have been made in order to 
investigate how to achieve early diagnosis and estimate prognosis with higher 
accuracy. Considering the great potential of miRNAs as putative cancer biomarkers, 
numerous studies have contributed to the identification of the most relevant miRNAs 
in PCa biology and the establishment of a PCa-specific miRNA expression profile 
[101-105]. For the purposes of this work, a literature review was conducted with the 
goal of assembling the currently knowns and unknowns about the deregulation and 
biological role of miR-182 and miR-375 in the context of PCa. 
2.4.1. miR-182 
 miR-182 belongs to the polycistronic miR-183/96/182 cluster located on 
human chromosome 7q32.2 [106]. Members of this cluster are expressed at high 
levels in most cancers and generally considered oncomiRs. Its upregulation in PCa 
compared to healthy prostatic tissue is strongly described. miR-182 has been reported 
to be upregulated in prostate tumors compared to healthy tissue in a genome-wide 
expression study [107], microarray analysis [108] with further qRT-PCR validation 
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[109], TCGA dataset [110], GEO dataset [111] and in prostate tumor xenograft tissues 
[112]. It is also overexpressed in DU145 cell line [113]. miR-182 is also highly 
expressed in tumors with higher Gleason grades [114]. Overexpression in metastatic 
vs localized PCa was also reported in GEO dataset [115].  
 As a biomarker, miR-182 expression in cancer tissue has been shown to 
improve diagnosis [116] and predict disease progression after RP [117]. miR-182 
expression was recently found to be packaged in exosomes broadening their potential 
as noninvasive biomarkers [118]. However, to the best of our knowledge no evidence 
of miR-182 differential expression in biofluids such as plasma in the context of PCa 
has been published. 
 Regarding miR-182 biological role, miR-96/182/183 cluster may be involved in 
suppression of zinc transporters and thus may play an oncogenic role since zinc is 
thought to have a protective role against PCa [108]. Importantly, miR-182 have been 
shown to promote cell invasion and proliferation by directly targeting FOXF2, RECK, 
MTSS1 [119], FOXO1 [120] and ARRDC3 [121] and also in PC3 cells by targeting 
NDRG1 [122]. miR-182 may support angiogenesis through inhibition of PDH2 and 
FIH1, which are negative regulators of hypoxia-inducible factor 1α (HIF-1α) [123]. 
However, miR-182 has shown to reduce tumor invasion through inhibition of invasion-
promoting protein GNA13 [124] and to simultaneously inducing tumor growth self-
sufficiency and mesenchymal-epithelial transition (MET) through SNAI2 targeting 
[125]. miR-182 also inhibited cell proliferation on statin-treated [126] (targeting BCL2) 
and mangiferin-treated [127] prostate cell lines.  
2.4.2. miR-375 
 As one of the most consistently described miRNAs in PCa, miR-375 offers 
great potential as a diagnostic and prognostic biomarker. Overexpression of miR-375 
in primary PCa tissues vs matched normal prostatic tissue (MNPT) has been reported 
in several studies [101, 103, 109, 128-131], suggesting an intra-tumoral oncogenic 
role for miR-375 in PCa. miR-375 is included in a 3-miR panel able to identify 80% of 
patients (AUC = 0.88) [109] and in a 6-miR panel able to identify 70.8% of patients 
(AUC = 0.854) [129] thus potentially having diagnostic value. Although a correlation 
between miR-375 and clinicopathological variables was not found in three of the 
aforementioned studies [109, 128, 129], Selth and colleagues observed that intra-
tumoral miR-375 levels predict time to BCR after RP independently of GS and clinical 
stage [103]. 
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 Similarly, miR-375 shows a noteworthy potential as a circulating biomarker. 
Increased levels of miR-375 in serum of PCa patients have been consistently 
detected [101, 103-105, 130, 132], despite a notable exception described by 
Kachakova et al. who found circulating miR-375 to be downregulated in PCa 
compared to BPH controls [133]. Interestingly, overexpression of miR-375 has been 
mainly reported in advanced-stage PCa patients, particularly: metastatic CRPC 
patients vs healthy men [103, 104], CRPC vs low-risk localized PCa [130], 
disseminated PCa (N1/M1 and CRPC) vs both localized PCa and BPH controls [105] 
and metastatic vs localized PCa [101], which suggests that miR-375 role may have a 
particular focus on disease progression into more advanced stages. Upregulation of 
serum miR-375 was also found in localized PCa compared to both BPH and healthy 
controls [132], which is in agreement with the described miR-375 oncogenic role. 
Serum expression of miR-375 in combination with expression of its target protein 
suPAR is associated with lymph-node positivity [101] and with high tumor stages (T3/
T4 vs T1/T2) [132] and correlated with poor overall survival and BCR-free survival 
[132], thus reinforcing the prognostic value of miR-375. Studies on plasma-circulating 
microvesicles and exosomes have reported that exosomal miR-375 is overexpressed 
in metastatic vs non-metastatic PCa [134] and negatively associated with overall 
survival in CRPC patients [135]. miR-375 upregulation in PCa has also been 
described in other biofluids such as urine [136], although still further evidence is still 
needed. 
 Although the potential of miR-375 as a biomarker appears to be a common 
characteristic in PCa, its specific biologic role in tumor development is still unclear. 
miR-375 was reported to be a direct target of PHLPP1, a phosphatase and potent 
inhibitor of proliferative signaling pathways [131]; Sec23A, a protein transport 
mediator which was able to reduce growth properties of PCa cells in vitro [128]; and 
CBX7, a member of the Polycomb repressive complex I that was found to be 
downregulated in advanced PCa [137]. miR-375 also shows a positive association 
with AR: Chu et al. observed that AR-positive cell lines (22Rv1, C4-2, LNCaP) present 
higher expression levels and hypomethylation of miR-375, while AR-negative cell lines 
(DU145, PC-3) show the opposite profile. They suggested that AR promotes miR-375 
higher expression via promoter demethylation [138]. DHT-stimulated LNCaP cells 
release miR-375 to the incubation medium, further suggesting that miR-375 could be 
androgen-sensitive [139]. However, ectopic expression of miR-375 decreased 
invasion and migration in PC3, DU-145 and C4-2B cell lines and facilitated epithelial 
differentiation, intriguingly acting as a tumor supressor through a ZEB-1/miR-375/
YAP-1 pathway that regulates EMT in PCa cells [140]. Our research group recently 
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suggested a dual role for miR-375 in prostate carcinogenesis, acting both as an 
oncomiR in 22Rv1 cells and as a tumor suppressor miR in PC-3 cells [141]. Even 
though a potential dual role of miR-375 in different prostate tumors is a possible 
scenario, its biological role is still unclear and thus further research is still required. 
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Aim of this Study 
 Notwithstanding the substantially high worldwide incidence of PCa, most of the 
prostatic tumors are diagnosed at early stages, in which patients may benefit from 
radical curative therapy such as RP. However, a considerable proportion of patients 
submitted to RP still develop late events such as recurrence, castration-resistance 
and metastasis, even though their primary tumor had been surgically removed. 
Although several studies have reported differentially expressed miRNAs in PCa, that 
may act as potential diagnostic or prognostic biomarkers, little is known about 
changes in miRNA levels before and after radical therapy and their putative relevance 
as biomarkers of postoperative cancer-related late events. Therefore, we 
hypothesized that plasma-circulating miRNA levels might be able to discriminate 
patients that develop late events from patients that do not.  
 For the purposes of this work the following objectives were drawn: 
1. To assess miRNA levels in PCa and non-neoplastic tissue using the publicly 
available TCGA dataset;  
2. To confirm miRNA deregulation in tumorous tissues from patients included in the 
validation cohort; 
3. To determine miRNA levels in preoperative and postoperative plasma from 
patients included in the study cohort; 
4. To identify associations between miRNA expression levels and PCa patients’ 
clinicopathological features. 
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Material and Methods 
1. The Cancer Genome Atlas dataset 
 miRNA expression levels of 326 PCa and 50 non-neoplastic tissues were 
retrieved by in The Cancer Genome Atlas (TCGA) dataset and analysed by 
collaborators from Instituto de Investigação em Ciências da Vida e Saúde (ICVS) of 
the University of Minho (Braga, Portugal). 
2. Patients and sample collection 
 A total of 210 patients harboring PCa that were submitted to RP at Portuguese 
Oncology Institute of Porto (Porto, Portugal) between 2001 and 2012, were recruited 
for this study. Peripheral blood was collected into EDTA-containing tubes at two 
distinct time points: immediately before RP (1 day prior to surgery) and during routine 
patient follow-up, after treatment. Plasma was obtained from blood by centrifugation 
(2,000 rpm; 10 min; 4ºC) and subsequently stored at -80ºC until further use. Prostate 
specimens from a subset of 100 patients were frozen after surgical procedure and 
stored at -80ºC. After the presence of tumor was confirmed by hematoxylin-eosin 
staining procedure, histological slides from frozen tissue fragments were cut using a 
cryostat and posteriorly stored at -80ºC until further use. Healthy prostate specimens 
from a group of 15 patients who performed cystoprostatectomy due to bladder cancer 
were used as negative controls after confirmation of the absence of malignant 
prostatic tissue. 
 This study was approved by the institutional review board [Comissão de Ética 
para a Saúde-(IRB-CES-IPOFG-EPE 120/015)] of Portuguese Oncology Institute of 
Porto, Portugal. Informed consent was obtained from all patients according to 
institutional regulations. 
3. RNA extraction from Tissue 
 RNA from PCa tissue was isolated using Triple Xtractor Reagent (GRiSP, 
Porto, Portugal). Briefly, 1 mL of reagent was added to tissue slides with subsequent 
tissue homogenization using a Cordless Pestle Motor and Disposable Pestles (VWR, 
Radnor, PA, USA). 200 µL of chloroform were added and the mixture was thoroughly 
vortexed for 15 seconds. Samples were centrifuged (10,600 rpm; 15 min; 4ºC) using 
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Centrifuge 5430R (Eppendorf AG, Hamburg, Germany) for phase separation and 
RNA-containing upper aquous phase was mixed with 500 µL of isopropanol. After 10 
min of incubation samples were centrifuged (10,600 rpm; 10 min; 4ºC) for RNA 
precipitation and two consecutive wash-and-centrifugation cycles with 75% ethanol 
(8,400 rpm, 5 min, 4ºC) were performed. Supernatant was removed and remaining 
pellet was air-dried for 30 min. Resuspension with 30 µL of RNase-free water was 
performed following 30 min of incubation on ice. Tissue RNA concentration and purity 
were subsequently measured using Nanodrop ND-1000 spectrophotometer 
(NanoDrop Technologies). 
4. RNA extraction from Plasma 
 Circulating RNA extraction was obtained using miRNeasy Serum/Plasma Kit 
(Qiagen, Hilden, Germany). Briefly, 1 mL of QIAzol Lysis Reagent (Qiagen) was 
added to 200 µL of plasma to denature protein complexes and RNases. 200 µL of 
chloroform were added and samples were centrifuged (12,000g; 15 min; 4ºC) using 
Centrifuge 5430R (Eppendorf AG) to perform phase separation. 900 µL of ethanol 
were added to 600 µL of RNA-containing upper aqueous phase and thoroughly mixed. 
Washes and subsequent centrifugations were performed on RNeasy MinElute spin 
columns with RWT Buffer (10,000 rpm; 15 seg; 25ºC), RPE Buffer (10,000 rpm; 15 
seg; 25ºC) and 80% ethanol (10,000 rpm; 2 min; 25ºC). Columns were centrifuged 
with opened lids (13,000 rpm; 5 min; 25ºC) in order to dry the membrane. 14 mL of 
RNase-free water were added to the membrane and samples were centrifuged 
(13,000 rpm; 1 min; 25ºC)to elute RNA. RNA concentration and purity were posteriorly 
determined using Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies).  
5. cDNA synthesis 
 microRNA-specific cDNA synthesis was performed using TaqMan microRNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), following 
manufacturer’s instructions. Briefly, 100 ng of RNA in a volume of 5 µL were 
transferred to each well of a GRS 96w PCR plate (GRiSP) and the following mix was 
added per well: 0.15 µL of 100mM dNTPs; 1 µL of MultiScribeTM Reverse 
Transcriptase; 1.5 µL of 10x Reverse Transcription Buffer; 0.19 µL of 20 U/µL RNase 
inhibitor; and 4.16 µL of DNase/RNase-Free Water (GIBCO, Grand Island, NY, USA). 
3 µL of 5x TaqMan microRNA looped RT primer (Applied Biosystems) were added to 
each well and reverse transcription was performed with Veriti® Thermal Cycler 
(Applied Biosystems) within the following conditions: 30 min at 16ºC; 30 min at 42ºC; 
and 5 min at 85ºC (Figure 6). A 1:2 dilution with DNase/RNase-Free Water (GIBCO) 
was performed after cDNA synthesis. 
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 6. miRNA expression analysis 
 Measurement of miRNA expression was performed using specific TaqMan 
microRNA assays (Applied Biosystems). Target sequence of each miRNA as well as 
reference gene U6 snRNA are described in Table 2. Briefly, 4.5 µL of cDNA were 
transferred into each well of a 384-well plate and a mix of 0.5 µL of TaqMan assay and 
5 µL of NZYSpeedy qPCR Probe Master Mix (NZYTech, Lisboa, Portugal) was added 
per well. Triplicates were performed for each sample. PCR reaction was performed in 
a LightCycler 480 Instrument (Roche Diagnostics, Manheim, Germany) within the 
following conditions: 3 min at 98ºC (enzyme activation); 45 cycles of 10 s at 95ºC 
followed by 25 s at 60ºC (denaturation, annealing, extension & acquisition) and 30 s at 
37ºC (cooling; Figure 7). 
  
!24
Figure 6: Illustration of cDNA synthesis reaction (adapted from TaqMan microRNA Reverse 
Transcription Kit protocol).
Assay Target Sequence
hsa-miR-182 5’-UUUGGCAAUGGUAGAACUCACACU-3’
hsa-miR-375 5’-UUUGUUCGUUCGGCUCGCGUGA-3’
U6 snRNA
5’-GTGCTCGCTTCGGCAGCACATATACTAAAATTGGAACGA 
TACAGAGAAGATTAGCATGGCCCCCGCAAGGATGACACG 
CAAATTCGTGAAGCGTTCCATATTTT-3’
Table 2: Target sequence of TaqMan microRNA expression assays. 
 miRNA relative expression level was calculated by using comparative Ct 
method with U6 snRNA standing for as a reference gene. Relative expression was 
calculated under the following formula: 
Relative miRNA expression = 2 -(Ct (miRNA) - Ct (U6 snRNA)) 
7. Statistical analysis 
 Statistical analysis of obtained data was performed using SPSS 24.0 software 
for Mac (IBM-SPSS Inc., Chicago, IL, USA). Graphics were built using GraphPad 
Prism 7.0 software for Mac (GraphPad Software Inc., La Jolla, CA, USA). A p-value 
inferior to 0.05 was considered statistically significant for 2-group comparisons, while 
Bonferroni correction (p = 0.05 / n) was applied for comparisons between more than 
two groups (n equals the number of groups). 
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Figure 7: Illustration of qPCR reaction (adapted from TaqMan microRNA Reverse Transcription Kit 
protocol).
Results 
1. MicroRNA Expression from The Cancer Genome Atlas dataset 
  
 Our approach started by evaluating miRNA expression levels in malignant 
tissue and non-malignant prostatic tissue of patients that were retrieved from TCGA 
dataset. Comparison between tumor and normal samples as well as matched analysis 
between malignant and non-malignant tissue from the same patients were performed. 
Globally, miR-375 and miR-182 levels were significantly overexpressed in tumor 
compared to normal tissue. The same was found for paired PCa and normal samples 
(Figures 8-9). 
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Figure 8: Expression of miR-375 in malignant and normal tissue from TCGA dataset. miR-375 was 
found to be overexpressed in tumor tissue both in overall(A) and matched (B) comparisons.
BA
Figure 9: Expression of miR-182 in malignant and normal tissue from TCGA dataset. miR-182 was 
found to be overexpressed in tumor tissue both in overall(A) and matched (B) comparisons.
A B
2. MicroRNA Expression in PCa Tissue Validation Cohort 
 To give further insight about the upregulation of the previous two miRNAs in 
PCa and their putative oncogenic role, a validation cohort of 100 patients diagnosed 
with PCa and treated with RP, and 15 controls (patients without prostate cancer, 
submitted to cystoprostatectomy due to bladder cancer) was built. Our approach 
consisted of analysing differences in expression between patients and individuals not 
harboring PCa as well as associations with clinicopathological variables. Clinical and 
pathological characteristics of patients included in this study are depicted in Table 3. 
2.1. Tumor and MNPT: Expression Differences 
 We started by comparing miRNA levels between tumor and morphologically 
normal prostatic tissue (MNPT). miRNA expression levels were compared through 
Mann-Whitney non-parametric test. Both miR-375 (p = 0.0479) and miR-182 (p < 
0.0001) expression levels were significantly higher in tumor vs morphologically normal 
prostatic tissue (Figure 10).  
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Clinicopathological variables Plasma Cohort  
(n = 210)
Matched Tissue 
Cohort (n = 100)
Healthy Tissue 
Cohort (n = 15)
Age (years), median (range) 63 (46 - 76) 63 (46 - 73) 63 (45 - 80)
PSA at diagnosis (ng/mL), 
median (range)
8.38 (0.68 - 
42.66)
8.8 (2.40 - 42) n.a.
Follow-up time (days), median 
(range)
2133 (117 - 6015) 2776 (175 - 
5704)
n.a.
Biochemical Recurrence (BCR)
Yes: 95 (45.2%) 
No: 115 (54.8%)
Yes: 48 (48.0%) 
No: 52 (52.0%)
n.a.
Metastasis
Yes: 18 (8.6%) 
No: 192 (91.4%)
Yes: 11 (11.0%) 
No: 89 (89.0%)
n.a.
Pathological Stage (pT)
2: 85 (40.5%) 
3a: 96 (45.7%) 
3b: 29 (13.8%)
2: 45 (45.0%) 
3a: 37 (37.0%) 
3b: 18 (18.0%)
n.a.
Grade Group
1: 49 (23.3%) 
2: 75 (35.7%) 
3: 55 (26.2%) 
4: 10 (4.8%) 
5: 21 (10.0%)
1: 28 (28.0%) 
2: 28 (28.0%) 
3: 27 (27.0%) 
4: 4 (4.0%) 
5: 13 (13.0%)
n.a.
n.a. = not applicable
Table 3: Description of clinicopathological variables of patients included in this study.
 2.2. Correlation with Clinicopathological Variables 
 Next, we focused on analysing the relationship between tissue miRNA levels 
of our 100-patient cohort and the most relevant clinicopathological variables that 
represent features of the tumor specimen itself and patient-related variables at time of 
surgery. Gleason Grade Groups, Pathological Stage, preoperative PSA and age at 
time of surgery were selected. 
 The association between miRNA expression levels in PCa tissue and tumor 
aggressiveness, measured by the recently established Gleason Grade Groups was 
evaluated. The five different Grade Groups were merged into two categories: “low-
grade” (GG 1-3) and “high-grade” (GG 4-5) and miRNA levels between both 
categories were compared through Mann-Whitney non-parametric test. Although 
miR-375 expression levels did not differ among patients with different grades (p = 
0.2735), a trend for increased miR-182 levels in high-grade Groups (p = 0.0845) was 
found (see Annexes 1-2). Likewise, we searched for an association between miRNA 
expression levels and Pathological Stage (pT2, pT3a or pT3b) using Kruskal-Wallis 
(KW) one-way ANOVA test. However, no associations were found between miRs 
expression levels and pathological stage (miR- 375: KW: p = 0.5523; miR-182: KW: p 
= 0.1656; see Annex 3). 
  
 To assess correlation between tumorous miRNA levels and preoperative 
patients’ PSA levels, a linear regression model was built for each miRNA. Although 
miR-375 levels did not correlate with preoperative PSA (p = 0.1451), a significant 
inverse correlation was found between miR-182 expression and serum PSA levels (ρ 
= 0.0151; Figure 11). 
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Figure 10: miR-375 (A) and miR-182 (B) expression levels in tumor and healthy tissue. Both miR-375 
and miR-182 expression was significantly increased in tumor samples.
A B
  A similar approach was used to analyse the relationship between miRNA 
levels and patients’ age, but no correlation was found either for miR-182 (p = 0.6092) 
or miR-375 (p = 0.9299) (see Annex 4). 
2.3. Survival Analysis 
  
 To determine the predictive potential of tumor-expressed miRNAs in respect to 
cancer-related late events such as BCR and metastasis, we started by measuring the 
effect of tumoral miRNA expression on BCR-free survival time through a Kaplan-Meier 
survival analysis with median miRNA expression level as cutoff. Log-rank test was 
used for comparison of survival curves. No statistically significant difference was 
found for miR-375 (p = 0.4616; Figure) or miR-182 (p = 0.2658 Figure) expression 
levels and Disease-Free Survival or Metastasis-Free Survival (miR-375; p = 0.6553 or 
miR-182; p = 0.7630; see Annexes 5-6). 
 Construction of a Cox proportional-hazards regression model was used to 
identify the variables that independently predict the occurrence of BCR. Grade Group 
(p < 0.0001) was the only statistically significant predictor BCR-free survival time. The 
remaining variables such as pT stage (p = 0.3881), age (p = 0.9234), preoperative 
PSA (p = 0.2622), miR-375 (p = 0.9036) and miR-182 (p = 0.3636) did not reach 
statistical significance. Accordingly, only High Grade group independently associated 
with shorter metastasis-free survival time (p < 0.0001), whereas no additional 
associations were found for any of the other studied variables [pT stage (p = 0.2164), 
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Figure 11: Linear regression of miR-375 (A) and miR-182 (B) levels and preoperative PSA value of 
each patient. A statistically significant negative correlation was observed between miR-182 and PSA.
A B
age (p = 0.7044), preoperative PSA (p = 0.9989), miR-375 (p = 0.2867) and miR-182 
(p = 0.4772)]. 
3. Preoperative MicroRNA Expression in Plasma 
 After analysing miRNAs tumorous tissue expression, we evaluated miRNAs 
expression levels in preoperative and postoperative plasma of patients from our study 
cohort (n = 210). We started by analysing preoperative miRNA levels in plasma and 
searching for relevant associations with clinicopathological variables.  
3.1. Correlation with Clinicopathological Variables 
  
 We sought to evaluate the association between preoperative miRNA levels 
and the recently established Grade Groups. We dichotomized samples into two 
categories: low (1-3) and high (3-5) Grade Groups. Data were analyzed using Mann-
Whitney non-parametric test. Accordingly, no association was found between 
circulating miR-375 levels at time of RP and Grade Groups (p = 0.1616; Figure 12), 
whereas a significant increase of miR-182 levels was verified in High Grade Groups (p 
= 0.0310; Figure 13). 
 The association between preoperative miRNA levels and Pathological Stage 
was assessed through Kruskal-Wallis one-way ANOVA test for comparison between 
three groups. Statistically significant differences for miR-375 (p = 0.0099) and for 
miR-182 (0.0192) were found between pT2, pT3a and pT3b. Pairwise comparisons 
performed with Mann-Whitney non-parametric test showed that preoperative miR-375 
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Figure 12: miR-375 expression levels stratified by Grade Groups (A) and dichotomized into low and 
high grade (B). No significant differences between high and low Grade Groups were observed.
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levels in plasma were significantly increased among patients within pT3b comparing 
with pT3a (p = 0.0027) and pT2 (p = 0.0073). Moreover, significantly higher plasma-
circulating miR-182 levels were displayed by pT 3b compared to pT 2 (p = 0.0098) 
patients (Figure 14). 
 A putative association between circulating miRNA levels and preoperative PSA 
levels in serum was similarly evaluated through the establishment of a linear 
regression model. However, the obtained slope was not statistically significant for 
miR-375 (p = 0.6993) or miR-182 (p = 0.0606; Annex 7). A similar approach was 
conducted for preoperative plasma-circulating miRNA levels and patients’ age at the 
time of RP: a linear regression model was built, however the slopes were not 
statistically significant for miR-375 (p = 0.9353) or miR-182 (p = 0.4498; see Annex 8). 
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Figure 13: miR-182 expression levels stratified by Grade Groups (A) and dichotomized into low and high 
grade (B). A significant overexpression of plasma-circulating miR-182 was found in patients within higher 
Grade Groups.
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Figure 14: miR-375 (A) and miR-182 (B) expression levels stratified by pathological stage. A significant 
overexpression of both miR-375 and miR-182 was found in patients within higher stages.
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4. miRNA Plasma:tissue Ratio 
 After analysing the obtained levels of miR-375 and miR-182 in PCa tissue and 
plasma in a separate approach, we hypothesized that miRNA plasma:tissue ratio, i.e. 
tumor-normalized miRNA levels in plasma, might constitute a relevant indicator of 
disease extension and tumor aggressiveness as well as predictor of late progression 
events. 
4.1. Correlation with Clinicopathological Variables 
  
 In order to evaluate the existence of an association between miRNA 
plasma:tissue ratio and tumor aggressiveness Grade Groups or dichotomized Grade 
Groups [Low grade (GG 1-3) and High grade (GG 4-5)] were compared for miRNA 
levels by Mann-Whitney non-parametric test. However, no statistically significant 
associations were observed for miR-375 (p = 0.9855) or miR-182 (p = 0.5788) ratios 
(see Annexes 9-10). 
 A similar approach was conducted for miRNA plasma:tissue ratio levels and 
pathological stage. Kruskal-Wallis one-way ANOVA test was used for a global 
comparison between three groups. Statistically significant differences were found for 
miR-375 (p = 0.0022) between pT2, pT3a and pT3b, but not for miR-182 (p = 0.9985). 
Pairwise comparisons with Mann-Whitney non-parametric test, demonstrated that 
miR-375 plasma:tissue ratio was significantly increased among patients with pT3b 
compared with pT3a (p = 0.0028), while pT3a patients presented significantly lower 
miR-375 plasma:tissue ratio levels compared with pT 2 (p = 0.0110). Conversely, no 
statistically significant associations were found between miR-182 plasma:tissue ratio 
levels and pathological stage (Figure 15).  
  
 Regarding miRNA plasma:tissue ratio no correlation with preoperative PSA 
and patients’ age was found [PSA: miR-375 (p = 0.1854) and miR-182 (0.9537) 
(Figure); Age: miR-375 (p = 0.1153) or miR-182 (p = 0.2333)] (see Annexes 11-12). 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 4.2. Survival Analysis 
  
 The prognostic value of miRNA plasma:tissue ratio regarding BCR was 
evaluated through the establishment of a Kaplan-Meier survival analysis. Patients 
were dichotomized into “High miR ratio” and “Low miR ratio” categories with median 
expression of each miRNA used as cut-off. Log-rank test was used for comparison of 
survival curves. High mR-375 ratio was significantly associated with shorter BCR-free 
survival time (p = 0.0344), whereas no significant association was observed regarding 
miR-182 (p = 0.1442; Figure 16). An identical approach was carried out for miRNA 
plasma:tissue ratio and metastasis-free survival time. However, no significant 
differences were observed for miR-375 (p = 0.4692) and miR-182 (p = 0.9268) ratios 
(see Annex 13). 
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Figure 15: miR-375 (A) and miR-182 (B) plasma:tissue ratio levels stratified by pathological stage. 
Statistical significant differences were found for miR-375, but not for miR-182.
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Figure 16: Kaplan-Meier BCR-free survival time of patients with high and low preoperative miR-375 (A) 
and miR-182 (B) plasma-tissue ratio. Patients with high miR-375 levels had significantly shorter BCR-
free survival (p = 0.0344), while no significant association was registered for miR-182 (p = 0.1442).
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 With the goal of testing the relevance of miRNA ratio on survival time 
prediction compared to other clinicopathological variables, a Cox proportional-hazards 
regression model accounting for pT stage, Grade Group, age at diagnosis and PSA at 
diagnosis was performed. miR-375 ratio (p = 0.0439) and Grade Group (p = 0.0002) 
independently predicted the risk of developing BCR. The remaining variables such as 
pT stage (p = 0.7088), age (p = 0.7461), preoperative PSA (p = 0.1322) and miR-182 
(p = 0.452) did not present statistical significance. 
 Regarding metastasis-free survival, Grade Group (p < 0.0001) significantly 
associated with this outcome, however pT stage (p = 0.1581), age (p = 0.6699), 
preoperative PSA (p = 0.8196), miR-375 (p = 0.7034) and miR-182 (p = 0.5168) did 
not significantly predict the development of metastasis. 
5. Postoperative miRNA expression in Plasma 
 After studying circulating miRNA levels before RP, we focused on analysing 
miRNA levels after radical surgery and their putative value as markers of BCR and 
metastasis. We searched for differences in postoperative plasma-circulating miRNA 
levels according with patients’ outcome after surgery. From 198 patients whose follow-
up was obtained after outcome development, 115 did not display BCR (“no BCR”; 
control group), 70 presented BCR during follow-up (“BCR” group) and 13 developed 
metastatic disease (“metastasis” group). miR-375 and miR-182 expression levels 
among the three groups were compared through Kruskal-Wallis one-way ANOVA test 
and pairwise comparisons were performed using Mann-Whitney non-parametric test.  
  
 Kruskal-Wallis test (p = 0.0055) revealed significant differences for miR-375 
across the three groups. Pairwise comparisons showed significantly higher miR-375 
expression levels in plasma samples of patients that developed metastases (p = 
0.0034) compared patients that did not progress. No additional significant differences 
were observed, although trends for increased miR-375 levels between ‘BCR’ and ‘no-
BCR’ groups (p = 0.0462) and between ‘metastasis’ and ‘BCR’ patients (p = 0.0570) 
were observed. Contrarily, postoperative miR-182 levels did not significantly differ 
among the three groups (Figure 17). 
 A putative association between postoperative plasma-circulating miRNA levels 
and concomitant PSA levels was evaluated through construction of a linear regression 
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model. A statistically significant positive correlation with PSA was obtained for 
miR-375 (p < 0.0001), but not for miR-182 (p = 0.7210; Figure 18). 
 
 In a similar approach, a correlation between postoperative plasma-circulating 
miRNA levels and the age of each patient at the same time point was evaluated 
through linear regression and Pearson coefficient determination. No statistically 
significant correlations were observed for miR-375 (p = 0.8564) or miR-182 (p = 
0.7078; see Annex 14). 
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Figure 17: Levels of postoperative plasma-circulating miR-375 (A) and miR-182 (B) according to the 
developed outcome after surgery. Significant differences were registered for miR-375, but not miR-182.
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Figure 18: Linear regression of miR-375 (A) and miR-182 (B) levels and postoperative PSA value of 
each patient. A statistically significant positive correlation was observed between miR-375 and PSA.
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Discussion 
 Since their first report in the context of malignant disease in 2002, miRNAs 
have shown enormous potential as cancer biomarkers. Particularly, the stable 
circulation of miRNAs in body fluids such as plasma has been consistently described 
since 2008 and greatly broadens the usefulness of miRNAs as biomarkers in a time 
when great efforts are being made for the identification of new non-invasive methods 
of diagnosis, prognosis and personalized follow-up. 
 In a previous study from our research group, which constitutes the basis for 
this dissertation, a panel of 17 miRNAs were found to be overexpressed in PCa tissue 
compared to matched normal prostate tissue (MNPT) by microarray analysis. miR-182 
and miR-375 were then selected for further studies and miR-182 and miR-375 
overexpression in PCa (n = 80) vs MNPT (n = 15) was validated. We firstly decided to 
obtain further evidence of miRNA deregulation in malignant tissue by assessing miR 
expression both in the publicly available TCGA genomic dataset and in a larger patient 
cohort. Indeed, we confirmed that miR-375 and miR-182 were overexpressed in PCa 
cases from TCGA dataset compared to normal controls both globally as well as in 
matched tissues comparison. Similarly, miR-375 and miR-182 were overexpressed in 
PCa tissues from our 100-patient cohort compared to MNPT controls, thereby 
supporting their previously described oncogenic role in prostate carcinogenesis [141]. 
 Because the main goal of this study was to evaluate variations in patient 
miRNA expressing profile during follow-up after radical prostatectomy, it seemed 
pertinent to assess if selected miRNAs were not only overexpressed in patients vs 
healthy controls but also similarly upregulated in tumors with different 
clinicopathological features. However, no statistically significant differences were 
found for miR-375 among patients within different Grade Groups or Pathological 
Stage and no correlations with age at time of surgery and preoperative PSA were 
established, either, suggesting that miR-375 levels do not reflect the extension and 
the histological aggressiveness of the tumor. Survival analysis did not disclose any 
significant association between miR-375 expression and BCR- and metastasis-free 
survival time. Likewise, no statistically significant associations were found between 
miR-182 levels and pathological stage, preoperative PSA and age at time of 
diagnosis, disease- and metastasis-free survival excepting a trend for higher miR-182 
expression in patients within higher Grade Group. Therefore, both miR-375 and 
miR-182 arise as putative oncomiRs in the context of PCa since their expression is 
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increased in tumor cells compared to non-neoplastic prostatic cells, although miR-375 
and miR-182 levels in PCa do not associate with standard parameters predictive of 
clinical aggressiveness. 
 Subsequently, we measured miR-375 and miR-182 circulating levels (plasma) 
in a 210-patient cohort in two different time points: immediately before RP and during 
patient follow-up. We started by analysing preoperative miRNA levels and their 
association with clinicopathological features. Interestingly, circulating miR-375 levels 
were significantly higher in patients staged pT3b compared to those staged pT3a and 
pT2. Circulating miR-182 were also found upregulated in patients staged pT 3b vs. 
pT2 and miR-182 overexpression in patients with higher grade group was similarly 
found. No additional statistically significant results were observed. Recalling that pTb 
represents extraprostatic extension through invasion of seminal vesicles, conveying a 
high risk of PCa dissemination, miR-375 and miR-182 upregulation in plasma might 
reflect increased tumor burden and, eventually, the occurrence of imagiologically 
undetected metastatic disease. Therefore, and contrarily to their expression patterns 
in tissue, miR-375 and miR-182 in plasma may represent early markers of PCa 
progression. 
  
 Due to the fact that both miRNAs (miR-375 and miR-182) present distinct 
associations with clinicopathological parameters depending whether expression is 
evaluated in PCa tissue or plasma, we hypothesized that miRNA plasma:tissue ratio, 
an indicator of tumor-normalized miRNA levels in circulation, might constitute an 
indicator of disease extension and tumor aggressiveness as well as a predictor of late 
progression events. Interestingly, we found that miR-375 ratio is significantly 
increased in patients within stage pT3b vs stage pT3a. Moreover, survival analysis 
revealed that patients with high miR-375 ratio display significantly shorter BCR-free 
survival time. Building of a Cox proportional-hazards regression model accounting for 
the remaining parameters confirmed that miR-375 ratio independently predicts for risk 
of BCR. Contrarily, we did not find any statistically significant associations between 
miR-182 ratio and clinicopathological parameters. We hypothesized that 
measurement of miRNA plasma:tissue ratio could add prognostic value to miR-375, 
being a potentially more relevant prognostic indicator than miRNA levels in plasma or 
tissue per se. However, miR-182 ratio does not match the associations found for 
plasma-circulating miR-182, which could suggest that miR-182 might not have 
prognostic value on its own and its levels in plasma mostly reflect tumor extent before 
surgery. 
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 To clarify our hypotheses, we sought to analyse miRNA expression in plasma 
during patient follow-up, after RP, and to determine whether their expression predicts 
for late progression events such as BCR or metastasis. Among our 210-patient cohort, 
115 patients did not developed recurrence, 77 patients developed BCR without 
metastasis and 18 patients developed metastasis. For this analysis, patients whose 
follow-up plasma was obtained before the development of each outcome (BCR or 
metastasis) were excluded, since miRNA levels could not chronologically reflect the 
presence of the outcome. Thus, seven patients from BCR subgroup and five patients 
from metastasis subgroup were excluded and miRNA levels from 198 patients were 
analysed. Interestingly, miR-375 levels were higher in patients that experienced BCR 
or metastization, although statistical significance was only reached for the latter, the 
former only disclosed a trend. Furthermore, a positive correlation was found between 
plasma-circulating miR-375 and postoperative PSA levels, which are routinely used to 
monitor PCa patients. Thus, it will be interesting to determine whether miR-375 might 
complement or eventually replace serum PSA as a follow-up biomarker. 
 Indeed, the observed global trend of higher levels among patients with worse 
outcome, strongly suggests that miR-375 may increase during follow-up time in 
parallel with PCa progression and may, thus, constitute a novel biomarker. Positive 
correlation with serum PSA, the only currently used biomarker for PCa progression 
after radical treatment, further supports the use of miR-375 as a disease marker. 
Moreover, this finding is in agreement with the predictive potential of miR-375 ratio, 
suggesting that miR-375 plasma:tissue ratio reflects tumor extension and predicts 
BCR-free survival, whereas postoperative plasma-circulating miR-375 might be a 
marker of disease progression. Contrarily, the results disclosed for miR-182 suggest 
that miR-182’s role in prostate carcinogenesis should be mostly during early stages of 
PCa development rather than disease progression after treatment.  
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Conclusions & Future Perspectives 
 Comparing the obtained results with the previously published reports, we 
suggest that miR-182 plays an oncogenic role in the earliest steps of PCa progression 
due to its overexpression in malignant tissue vs MNPT. Plasma-circulating levels of 
miR-182 reflect early dissemination stages of PCa, however the lack of prognostic 
value or miR-182 plasma:tissue ratio before RP as well as the absence of a significant 
association between postoperative miR-182 levels in plasma and disease progression 
after radical surgery suggests that miR-182 may act as an oncomiR in early PCa 
progression stages rather than a marker of disease progression after treatment. 
 Contrarily, our results suggest that miR-375 might be implicated in the earliest 
stages of PCa but also constitute an independent predictor of BCR and a marker of 
postoperative disease progression, thus, potentially able to complement and/or 
replace serum PSA as a follow-up biomarker. Moreover, measurement of miR-375 
plasma:tissue ratio before surgery, rather than plasma-circulating levels per se, may 
assist in prognostic assessment to currently used tools. 
 For the purposes of future research we suggest that systematic collection of 
peripheral blood during patient follow-up and the respective measurement of miR-375 
levels could be helpful to obtain further evidence of miR-375 performance as a follow-
up biomarker, since it would enable the construction of a miR-375 expression profile 
throughout follow-up time that might predict the occurrence of late events such as 
BCR and metastasis and therefore allow an early intervention that could increase 
patient survival and thus improve their quality of life.  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Annex 1: miR-375 expression levels stratified by Grade Groups (A) and dichotomized into low and 
high grade (B). No significant differences between high and low Grade Groups were observed.
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Annex 2: miR-182 expression levels stratified by Grade Groups (A) and dichotomized into low and 
high grade (B). A tendency of overexpression was found in patients within higher Grade Groups.
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Annex 3: miR-375 (A) and miR-182 (B) expression levels stratified by pathological stage. No 
statistically significant differences were found.
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Annex 4: Linear regression of intra-tumoral miR-375 (A) and miR-182 (B) levels and age of each 
patient at time of RP. No statistically significant correlations were observed.
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Annex 5: Kaplan-Meier BCR-free survival of patients with high and low intratumoral miR-375 (A) and 
miR-182 (B) levels. No statistically significant differences between survival curves were obtained.
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Annex 6: Kaplan-Meier metastasis-free survival of patients with high and low intra-tumoral miR-375 
and miR-182 levels. No statistically significant differences between survival curves were obtained.
A B
 !42
40 50 60 70 80
0
1
2
3
miR-375 & Age at time of RP
Age
m
iR
-3
75
40 50 60 70 80
0.0
0.1
0.2
0.3
0.4
0.5
miR-182 & Age at time of RP
Age
m
iR
-1
82
Annex 8: Linear regression of miR-375 (A) and miR-182 (B) levels and age of each patient at time of 
RP. No statistically significant correlations were observed.
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Annex 7: Linear regression of miR-375 (A) and miR-182 (B) levels and preoperative PSA value of 
each patient. No statistically significant correlations were observed.
A B
GG1 GG2 GG3 GG4 GG5
0.001
0.01
0.1
1
10
100
R
el
at
iv
e 
m
iR
-3
75
 e
xp
re
ss
io
n
miR-375 ratio: Grade Groups
n = 28 n = 28 n = 27 n = 4 n = 13
GG 1-3 GG 4-5
0.001
0.01
0.1
1
10
100
R
el
at
iv
e 
m
iR
-3
75
 e
xp
re
ss
io
n
miR-375 ratio: Grade Groups
n = 83 n = 17
Annex 9: miR-375 plasma:tissue ratio levels stratified by Grade Groups (A) and dichotomized into 
low and high grade (B). No significant differences between high and low Grade Groups were 
observed.
A B
 !43
40 50 60 70 80
0
5
10
15
Age & miR-375 ratio
Age
m
iR
-3
75
40 50 60 70 80
0
5
10
15
20
Age & miR-182 ratio
Age
m
iR
-1
82
Annex 12: Linear regression of miR-375 (A) and miR-182 (B) levels and age of each patient at time of 
RP. No statistically significant differences were obtained.
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Annex 10: miR-182 plasma:tissue ratio levels stratified by Grade Groups (A) and dichotomized into 
low and high grade (B). No significant differences between high and low Grade Groups were observed.
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Annex 11: Linear regression of miR-375 (A) and miR-182 (B) levels and preoperative PSA value of 
each patient. No statistically significant differences were obtained.
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Annex 13: Kaplan-Meier BCR-free survival time of patients with high and low preoperative miR-375 
(A) and miR-182 (B) plasma-tissue ratio. No statistically significant associations were found. 
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Annex 14: Linear regression of miR-375 (A) and miR-182 (B) levels and age of each patient at follow-up 
time. No statistically significant correlations were observed.
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